This Month in Cervical Cancer Research

October was a busy month for cervical cancer research, and the work stretched across the full arc of care, from the first HPV vaccine dose to life after treatment. The biggest threads were a fresh pooled analysis confirming that adding immunotherapy to chemotherapy helps people with recurrent or metastatic disease live longer, new evidence that HPV-based screening can be safely simplified (including for women vaccinated as adolescents), and a cluster of studies on making radiation treatment gentler and more precise. Prevention research remained strong and global: teams in Kenya, Cameroon, India, Lesotho, Egypt, and across Europe examined why vaccination and screening still fail to reach so many people. Running through all of it was the field's defining tension: cervical cancer is one of the most preventable cancers, yet the tools that prevent it are still unevenly shared, with the heaviest burden falling on women in low- and middle-income countries.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

Immunotherapy keeps reshaping care for advanced and recurrent cervical cancer

For people whose cervical cancer has returned or spread, immune checkpoint inhibitors (drugs that remove a brake on the immune system so it can attack cancer) are now part of standard first-line treatment. This month's studies help answer the next set of practical questions: how much benefit to expect, what comes after immunotherapy, and how to manage its side effects.

• If you are facing recurrent or metastatic cervical cancer, this pooled analysis adds confidence that adding a checkpoint inhibitor to chemotherapy (with or without bevacizumab) helps people live longer. Researchers combined six randomized trials with 2,242 participants and found median overall survival of 28.7 months with the combination versus 19.4 months without it, and median time before the cancer grew of 12.0 versus 8.7 months. Serious side effects were modestly more common with the combination, so close monitoring still matters. (Read the full paper)

• A newer type of immunotherapy may offer another strong first-line option. In a multicenter retrospective study led by investigators in China, 52 people with newly treated recurrent or metastatic disease received cadonilimab (a bispecific antibody, a single drug that blocks two immune brakes, PD-1 and CTLA-4) with chemotherapy; 75% saw their tumors shrink and 82.6% were alive at two years. Because the study was small, retrospective, and had no comparison group, these results need confirmation in randomized trials. (Read the full paper)

• If immunotherapy has already stopped working for you, a second course may still help some people. A team at Ohio State University reviewed 50 patients with recurrent endometrial or cervical cancer who received a second round of immunotherapy; among the 14 with cervical cancer, the disease was held in check in 64.3% and median time before progression was 9.7 months, although only 14.3% had tumors shrink. The findings come from a single center, so the authors call for prospective studies to identify who benefits most. (Read the full paper)

• How doctors taper steroids after a serious immune-related side effect appears to matter. In 63 people with gynecologic cancers (27% with cervical cancer) treated at Ohio State University, steroid tapers shorter than 28 days or outside national (NCCN) guidance were more often followed by extra medications and restarting steroids. Rates of hospitalization did not differ, but the results support asking your care team how a taper will be paced and monitored. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Radiation treatment is becoming more precise and easier to get through

For locally advanced cervical cancer, meaning disease that has grown beyond the cervix but has not spread to distant organs, chemoradiation (chemotherapy given alongside radiation) remains the backbone of treatment. This month's work focused on making that treatment safer, more tailored, and easier to tolerate.

• A planning approach that shields bone marrow from radiation, combined with a preventive long-acting white blood cell booster, may make chemoradiation safer. In a phase II trial of 54 patients in Sichuan, China, only 13% developed severe neutropenia (a dangerous drop in infection-fighting white cells), well below the 30% benchmark the investigators set, and 85.2% completed all four planned chemotherapy cycles. The single-arm design means randomized trials are still needed. (Read the full paper)

• Radiation that adapts each day to your changing anatomy may protect healthy organs better, but the benefit varies from person to person. Researchers simulated online adaptive radiotherapy for 10 patients and found that daily re-planning improved coverage of the tumor while keeping or lowering dose to nearby organs, with gains partly tied to how much bladder filling changed. This was a planning study, not a treatment trial. (Read the full paper)

• For brachytherapy that uses needles placed directly into the tumor (interstitial brachytherapy), a different sedative may make repeated sessions safer. In a randomized trial of 100 patients at Sichuan Cancer Hospital, remimazolam caused side effects such as breathing problems or low blood pressure in 17.8% of sedation sessions, compared with 59.4% for the commonly used drug propofol. Sleep quality did not differ between the groups. (Read the full paper)

• A PET/CT scan after chemoradiation may give a clearer picture of whether treatment worked than standard imaging alone. Researchers at Tokushima University studied 73 patients and found that metabolic measures on post-treatment PET/CT were strongly reassuring when negative and tracked with local tumor control, while standard size-based response criteria did not. The study was retrospective and from one center. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

HPV vaccination works, and the work now is reaching everyone

HPV vaccination prevents most cervical cancers, and the science on its effectiveness is settled. This month's research shows that the remaining challenge is delivery: who gets vaccinated, who pays, and who gets left out.

• Europe has made real progress, but coverage still falls well short of the World Health Organization's 90% target. An analysis of 43 European countries from 2010 to 2023 found that coverage among 15-year-old girls rose to about 40% within two years of national program launch and leveled off at 55% to 60% by year five. School-based programs drove faster gains, while public doubts about vaccine safety held coverage back. (Read the full paper)

• In Kenya, interviews with 52 community leaders, health workers, and decision-makers showed what helps and what hinders vaccination. Adding school- and community-based delivery to clinic-based vaccination increased coverage, while training gaps, logistics, missing parental consent, and myths slowed it down. The authors highlight early engagement of communities as a practical fix. (Read the full paper)

• Sustainable funding remains a major barrier across Africa. A scoping review of 27 studies by researchers at the Cephas Health Research Initiative found heavy reliance on donor support, particularly from Gavi, with limited domestic co-financing; the financial cost of fully vaccinating one girl ranged from about US$8 to US$54 in 2025 dollars. Building national budgets for HPV vaccination is a key step toward elimination. (Read the full paper)

• People with disability are being missed. A scoping review from Australia found inequalities in HPV vaccination coverage for people with disability in all 33 studies identified, often driven by mistaken assumptions about sexual activity and a lack of recommendations from health professionals. No studies came from low- and middle-income countries, a major evidence gap. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

HPV-based screening is getting smarter, simpler, and better tested

HPV testing is now the preferred way to screen for cervical cancer. This month's studies refine how to use it: who may need less screening, which low-cost tests work, and how to triage a positive result when resources are limited.

• A negative HPV test remains very reassuring, and this Swedish study clarifies the rare exceptions. Among 3,000 women diagnosed with invasive cervical cancer from 2019 to 2024, researchers at Karolinska Institutet found that 8.1% had a negative HPV test close to diagnosis; these women were older and more often diagnosed at an advanced stage, and more than half had no earlier HPV test on record. Regular participation in screening, rather than a single test, appears to be the key protection. (Read the full paper)

• Women vaccinated as adolescents may safely need less screening. In a Finnish controlled trial following 5,626 women vaccinated against HPV16/18 in 2007 to 2009, screening once at age 28 was found to be non-inferior to screening at ages 22, 25, and 28 for finding precancerous changes over 16 years. Most changes were caused by HPV types the vaccine did not target, and the authors suggest screening for vaccinated women could be reduced to a minimum. (Read the full paper)

• Affordable point-of-care HPV tests could expand screening in low-resource settings. Researchers at the All India Institute of Medical Sciences and the International Agency for Research on Cancer validated four tests developed in India using 1,159 samples from Argentina and Costa Rica. One test targeting eight high-risk HPV types, Truenat-HR-HPV-Plus, met international validation criteria (80.4% sensitivity and 91.5% specificity for high-grade precancer), while two others did not. (Read the full paper)

• For women who collect their own samples and test HPV-positive, knowing the specific HPV type can guide next steps when resources are limited. Analyzing 868 HPV-positive women from the 3T study in Cameroon, 9% had high-grade precancer, with HPV16 and HPV18/45 carrying the highest risk. Where cytology or visual inspection is unavailable, directly treating women with any of the eight highest-risk types offered the best balance of benefits and harms. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Researchers are refining how precancerous changes are tracked and treated

CIN, precancerous cervical cell changes graded 1 to 3, can be found and treated before cancer develops. This month's studies looked for better ways to tell which changes need treatment and how to follow people afterward.

• A DNA-based test may work especially well for postmenopausal women. Investigators at Zhejiang Provincial People's Hospital studied 705 women undergoing colposcopy and found that methylation tests of the PAX1 and JAM3 genes (chemical tags on DNA that change as cells become abnormal) detected high-grade changes with 90.0% and 82.5% sensitivity after menopause, versus about 60% before menopause. Combining the two tests raised sensitivity in premenopausal women to 72.7%. (Read the full paper)

• Not every promising follow-up test works, and negative results help too. Among 91 patients treated with LEEP (an outpatient procedure that removes abnormal tissue with a thin electrical wire loop) in Nanning, China, HPV E6/E7 mRNA testing before or after the procedure did not predict which patients would have a recurrence. The authors call for better biomarkers to guide follow-up care. (Read the full paper)

• Immune signals in cervical mucus may one day help gauge how serious a lesion is. Researchers in Geneva measured 27 immune messengers (cytokines) in 90 women and found distinct patterns by lesion grade, including higher IL-1β and lower IP-10 in high-grade lesions. The treatment-response findings were exploratory and based on only 15 women. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Health disparities and global equity remain the central challenge for prevention

Cervical cancer is largely preventable, yet nearly all deaths occur where screening and treatment are hardest to reach. This month's studies looked closely at the practical, financial, and cultural barriers that keep women from care, in Africa, the Middle East, and high-income countries alike.

• Single-visit "screen-and-treat" programs may be the most practical path in Sub-Saharan Africa. A scoping review from the Universidad de Navarra found that HPV-based screening is consistently more accurate than older methods, yet coverage remains low; single-visit approaches reduce the number of women lost to follow-up, self-sampling is widely acceptable, and thermal ablation is a feasible, well-tolerated treatment. (Read the full paper)

• Even when screening is free, getting to it is not. Surveying 100 women at Lesotho's Senkatana Cervical Cancer Center of Excellence revealed an average cost of about US$21 per visit, mostly from transport and related costs and lost earnings; 91% had to return for results, and the full screen-to-treatment pathway cost an estimated 11% to 17% of average monthly income. (Read the full paper)

• In Egypt, in-depth interviews with 22 women revealed layered barriers to screening. A study from Cairo University described stigma and modesty norms, the need for family permission, fatalistic and religious beliefs, and structural obstacles such as cost and a shortage of female providers. The authors call for culturally grounded approaches that engage families and faith leaders. (Read the full paper)

• Self-collection could make screening safer and more respectful for people with intellectual disability. Interviews from the University of Sydney with people with intellectual disability, their supporters, disability service leaders, and clinicians found that self-collection restored a sense of control and felt less invasive, but ableist assumptions and clinician-centered pathways still limited access. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Fertility, hormones, and well-being after treatment are getting closer attention

Many people diagnosed with cervical cancer are of reproductive age, and treatment can affect fertility, hormones, and emotional health for years. This month's research offers clearer guidance and highlights gaps in long-term care.

• If preserving fertility matters to you, new French guidance clarifies who may be a candidate. The French Cervical Cancer Guidelines Group concluded that cone biopsy can be offered for the earliest-stage disease (FIGO 2018 stage IA1 to IA2) and simple trachelectomy (removal of the cervix while keeping the uterus) may be preferred for stage IB1 disease without spread into lymph or blood vessels. Moving the ovaries out of the radiation field (ovarian transposition) preserved ovarian function in about two-thirds of patients. (Read the full paper)

• Hormone therapy after radiation is common but often needs fine-tuning. Among 51 patients aged 45 or younger treated with radiation in British Columbia, 74.5% were prescribed menopausal hormone therapy, starting a median of 3.5 months after treatment, and most needed dose or formulation changes. The authors call for standardized counseling pathways, a useful topic to raise with your care team. (Read the full paper)

• Anxiety and depression are common after a cervical cancer diagnosis, and nutrition may be part of the picture. A narrative review from Grigore T. Popa University of Medicine and Pharmacy in Iasi, Romania, links poor nutritional status and oxidative stress (a buildup of cell-damaging molecules) to greater psychological burden, and argues for care that addresses both body and mind. (Read the full paper)

• Trust in your oncologist can now be measured more reliably in Ethiopia. Researchers at Addis Ababa University adapted a trust scale into a five-item Amharic version for 197 patients; it showed strong reliability, and higher trust was linked with more shared decision-making. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Molecular profiling is starting to sort cervical cancers into treatable groups

Cervical cancers are not all the same at the molecular level. Studies this month mapped those differences, including in rare and aggressive subtypes, laying groundwork for more personalized treatment.

• A detailed molecular map of cervical cancer in Chinese patients points to possible new treatment targets. Analyzing 112 tumors alongside normal tissue, a team led by investigators in Harbin, Hainan, and Wuhan identified PIK3CA, EP300, and MPRIP as key drivers, flagged LAMC2 as a candidate diagnostic and therapeutic target, and sorted tumors into three immune profiles. Because most molecular data so far come from Western populations, this resource helps close a gap. (Read the full paper)

• For neuroendocrine carcinoma of the cervix, a rare and aggressive subtype, an MRI-based model may help predict lymph node spread before surgery. In 133 patients across two centers, the radiomics model (which extracts patterns from MRI images that the eye cannot see) correctly identified node spread in 81.3% of affected patients in external testing, compared with 56.3% for conventional MRI reading, although the overall difference was not statistically significant. (Read the full paper)

• Inherited variation in an immune-related gene may influence outcomes, but the signal is not yet strong. Using data from 173 patients in The Cancer Genome Atlas and 52 Brazilian patients, researchers linked certain ERAP1 gene variants with survival, though the association did not hold once other factors were accounted for. Larger studies are needed. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

General and basic-science research continues to map how cervical tumors grow and resist treatment

Laboratory and computational studies explore how cervical tumors grow, evade the immune system, and resist treatment. This month's work in this area is early-stage science, listed in the citations so you can find it.

Check the citations section for a comprehensive list of publications associated with this topic.

What Does This Mean for Me?

If you have just been diagnosed: Treatment depends on stage, so ask your care team what stage your cancer is and whether fertility preservation is an option for you. This month's French guidance shows that for some early-stage cancers, removing only the cervix (or even a cone of tissue) can be safe. If you will receive radiation, ask whether moving the ovaries out of the radiation field is possible and what hormone support will look like afterward. Questions to ask: "Am I a candidate for fertility-sparing surgery?" and "How will we manage menopause symptoms after treatment?"

If you are receiving chemoradiation for locally advanced disease: Researchers are actively working to make this treatment easier to get through, from radiation plans that spare bone marrow to gentler sedation for brachytherapy. Ask how your team protects your blood counts during treatment, and how they will check whether treatment worked once it ends; some centers use PET/CT for this. If you have vaginal dryness or discomfort after radiation, raise it; it is common and treatable.

If your cancer has come back or spread: Immunotherapy combined with chemotherapy is now well supported as a first option, and this month's pooled analysis confirms it helps people live longer. If immunotherapy has already been used, a second course may still help some people, and newer drugs such as bispecific antibodies are being studied. If you develop a serious immune-related side effect, ask how your steroid taper will be paced. Questions to ask: "Am I eligible for a clinical trial?" and "What is the plan if this treatment stops working?"

If you are focused on prevention or screening: HPV vaccination and HPV-based screening remain the most powerful tools against cervical cancer. A negative HPV test is very reassuring, but regular screening matters; if it has been a while, ask about your next test and whether self-collection is available where you live. If you were vaccinated as a young teen, future guidelines may recommend fewer screenings, so ask your provider what applies to you. Parents can ask about vaccinating children at the recommended age, ideally through school or community programs.

Clinical trials are how every advance described here was made. If you are interested in research participation, ask your care team about trials you may qualify for, or search ClinicalTrials.gov. OCRA's patient support resources can also help you find information and connect with others in the gynecologic cancer community.

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

The citations below are grouped to match the sections above. "Directly referenced" papers are the ones summarized in that section; the remaining entries are on-topic papers either not discussed above or behind access restrictions.

Immunotherapy keeps reshaping care for advanced and recurrent cervical cancer

Directly referenced:

1. Luo R, et al. "Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy ± bevacizumab for recurrent or metastatic cervical cancer: a systematic review and meta-analysis of randomized controlled trials." Front Immunol. October 19, 2026. PMID 42973905. https://doi.org/10.3389/fimmu.2026.1972995

2. Li J, et al. "Anti-PD-1/CTLA-4 bispecific antibody-based combination therapy for cervical cancer: a multicenter study with biomarker analysis." Front Immunol. October 1, 2026. PMID 42889160. https://doi.org/10.3389/fimmu.2026.1967065

3. Chalif J, et al. "A second chance? Outcomes of immunotherapy retreatment after prior checkpoint inhibitor exposure in endometrial and cervical cancer." Gynecol Oncol. October 13, 2026. PMID 42868630. https://doi.org/10.1016/j.ygyno.2026.10.005

4. Velasquez J, et al. "How slow should we go? Variation and outcomes of steroid tapering for immunotherapy-related toxicities in gynecologic cancer." Gynecol Oncol. October 20, 2026. PMID 42900968. https://doi.org/10.1016/j.ygyno.2026.10.012

Additional open-access citations:

5. Shan B, et al. "Case Report: Severe multi-organ damage induced by cadonilimab: mechanism investigation and management strategies." Front Immunol. October 1, 2026. PMID 42889251. https://doi.org/10.3389/fimmu.2026.1961670 (case report of severe multi-organ toxicity with cadonilimab)

6. Almalki ZS, et al. "Cost-effectiveness of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for high-risk locally advanced cervical cancer in Saudi Arabia: A model-based economic evaluation." Medicine (Baltimore). October 2, 2026. PMID 42826320. https://doi.org/10.1097/MD.0000000000050990 (cost-effectiveness of pembrolizumab with chemoradiation, Saudi Arabia)

7. Cheng T, et al. "Evolving Systemic Intensification Strategies Beyond CCRT in Locally Advanced Cervical Cancer." Cancer Manag Res. October 28, 2026. PMID 42968957. https://doi.org/10.2147/CMAR.S637635 (review of systemic treatment intensification beyond chemoradiation)

8. Meek JM, et al. "Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer." Eur J Cancer. October 2026. PMID 42600508. https://doi.org/10.1016/j.ejca.2026.116984 (neoadjuvant chemotherapy and regulatory T cells)

Related citations, access restricted:

9. Goffinet L, et al. "[Metastatic or recurrent cervical cancer : current management and therapeutic perspectives]." Rev Med Liege. October 2026. PMID 42861532. https://pubmed.ncbi.nlm.nih.gov/42861532/ (license unconfirmed)

10. Duenas-Gonzalez A, et al. "Combination therapies for the treatment of locally advanced and advanced cervical cancer." Expert Opin Pharmacother. October 20, 2026. PMID 42867445. https://doi.org/10.1080/14656566.2026.2749633 (subscription access)

11. Sridhar S, et al. "Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated with Clinical Activity." Clin Cancer Res. October 1, 2026. PMID 42467245. https://doi.org/10.1158/1078-0432.CCR-26-0782 (restricted license, CC BY-NC-ND 4.0)

Radiation treatment is becoming more precise and easier to get through

Directly referenced:

12. Wang S, et al. "Combined Active Bone Marrow-Sparing Radiotherapy and Prophylactic PEG-rhG-CSF to Reduce Severe Neutropenia During Platinum-Doublet Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: A Phase II Trial." Cancer Med. October 2026. PMID 42860035. https://doi.org/10.1002/cam4.72366

13. Penney J, et al. "Patient-specific dosimetric impact of online adaptive radiotherapy for locally advanced cervical cancer." Biomed Phys Eng Express. October 16, 2026. PMID 42838081. https://doi.org/10.1088/2057-1976/aeb0b0

14. Wang Y, et al. "Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial." Ann Med. October 4, 2026. PMID 42829852. https://doi.org/10.1080/07853890.2026.2740294

15. Kishimoto Y, et al. "Utility of 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in assessing treatment response after chemoradiotherapy for cervical cancer." J Radiat Res. October 9, 2026. PMID 42560332. https://doi.org/10.1093/jrr/rrag060

Additional open-access citations:

16. Pang X, et al. "CBX4 and NOX4 Expression Are Associated With Chemoradiotherapy Response and Overall Survival in Locally Advanced Cervical Squamous Cell Carcinoma." Cancer Med. October 2026. PMID 42897395. https://doi.org/10.1002/cam4.72402 (CBX4 and NOX4 expression and chemoradiation response)

Related citations, access restricted:

17. Wang QX, et al. "Brachytherapy-based local radiotherapy improves survival in newly diagnosed metastatic cervical cancer." Clin Exp Metastasis. October 17, 2026. PMID 42891728. https://doi.org/10.1007/s10585-026-10438-6 (subscription access)

18. Prasartseree T, et al. "Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort." Brachytherapy. October 2, 2026. PMID 42823295. https://doi.org/10.1016/j.brachy.2026.08.004 (restricted license, CC BY-NC-ND 4.0)

HPV vaccination works, and the work now is reaching everyone

Directly referenced:

19. Pavia G, et al. "Human papillomavirus (HPV) Vaccination programmes across European countries: time-harmonized coverage among adolescent females, socioeconomic predictors, and impact on public interest." Vaccine. October 2026. PMID 42623713. https://doi.org/10.1016/j.vaccine.2026.129058

20. Owidi E, et al. "Multiple-level stakeholders' perspectives on barriers and facilitators of HPV vaccination delivery in Western and Central Kenya: a qualitative study." BMJ Public Health. October 8, 2026. PMID 42866410. https://doi.org/10.1136/bmjph-2026-005069

21. Aminu K, et al. "Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review." Health Sci Rep. October 2026. PMID 42799168. https://doi.org/10.1002/hsr2.73254

22. Walmsley S, et al. "HPV vaccination coverage and barriers for people with disability: A scoping review." Hum Vaccin Immunother. October 16, 2026. PMID 42886011. https://doi.org/10.1080/21645515.2026.2738264

Additional open-access citations:

23. Langhe R, et al. "Cultural and structural barriers to HPV vaccine acceptance among young women in the United Arab Emirates." PLoS One. October 30, 2026. PMID 42961930. https://doi.org/10.1371/journal.pone.0346507 (HPV vaccine barriers among young women, United Arab Emirates)

24. Xie M, et al. "Health information literacy mediates the relationship between active information seeking and HPV-related knowledge among female undergraduates: the moderating role of information channel characteristics." Front Public Health. October 1, 2026. PMID 42889210. https://doi.org/10.3389/fpubh.2026.1947194 (health information literacy and HPV knowledge, Chinese undergraduates)

25. Kariri YA, et al. "Sociodemographic correlates of human papilloma virus (HPV) and cervical cancer knowledge among Saudi women: A nationwide assessment." Medicine (Baltimore). October 2, 2026. PMID 42826274. https://doi.org/10.1097/MD.0000000000050955 (HPV and cervical cancer knowledge among Saudi women)

Related citations, access restricted:

26. Wieland U, et al. "[Vaccine prevention of HPV-associated diseases]." Dermatologie (Heidelb). October 2026. PMID 42726205. https://doi.org/10.1007/s00105-026-05786-z (subscription access)

27. Cordoba-Sanchez V, et al. "A cluster-randomized trial of the school-based 'Superprotegidas' behavioral intervention to improve HPV vaccination uptake in Colombian girls." Vaccine. October 2026. PMID 42753387. https://doi.org/10.1016/j.vaccine.2026.129172 (restricted license, CC BY-NC-ND 4.0)

28. Kyei GK, et al. "Achieving Cancer Prevention Equity: A Policy Analysis of American Cancer Society HPV Vaccination Guidelines." J Adv Nurs. October 2026. PMID 41510830. https://doi.org/10.1111/jan.70477 (restricted license, CC BY-NC-ND 4.0)

29. Dickerson JC, et al. "Effect of a comic book-based educational intervention on human papillomavirus vaccine knowledge and safety perception among girls aged 9-14 in Nigeria." Vaccine. October 5, 2026. PMID 42832933. https://doi.org/10.1016/j.vaccine.2026.129194 (restricted license, CC BY-NC-ND 4.0)

30. Yu Z, et al. "Evolving Roles in Decision-Making About Human Papillomavirus Vaccination Among Middle School Girls in Yinzhou of Ningbo, Eastern China: A Qualitative Study With a Focus on the Educational Sector as an Influential Player." Health Promot Pract. October 15, 2026. PMID 42878181. https://doi.org/10.1177/15248399261493508 (subscription access)

31. Malibwa D, et al. "Influence of COVID-19 and COVID-19 rumours on trust and uptake of single-dose male HPV vaccination in the Add-Vacc cluster-randomised trial, northwest Tanzania." Vaccine. October 9, 2026. PMID 42854550. https://doi.org/10.1016/j.vaccine.2026.129231 (restricted license, CC BY-NC-ND 4.0)

32. McClymont E, et al. "Long-term immunogenicity and efficacy of the quadrivalent human papillomavirus vaccine in women with HIV: a longitudinal cohort study." Lancet HIV. October 5, 2026. PMID 42833230. https://doi.org/10.1016/S2352-3018(26)00204-3 (subscription access)

33. Armaroli P, et al. "Population-Based First Estimates of the Effect of HPV Vaccination in Three Italian Areas Covered by Organised Cervical Screening." Int J Cancer. October 2026. PMID 42084786. https://doi.org/10.1002/ijc.70536 (free to read, no reuse license)

HPV-based screening is getting smarter, simpler, and better tested

Directly referenced:

34. Hassan SS, et al. "Invasive Cervical Cancers After an HPV-Negative Test: Insights From HPV Testing Histories." Int J Cancer. October 10, 2026. PMID 42857941. https://doi.org/10.1002/ijc.70783

35. Lehtinen M, et al. "Controlled Trial of Cervical Cancer Screening Frequency Among Human Papillomavirus Vaccinated Women II: Cervical Pre-Cancer End-Points by Specific Non-Vaccine HPV Types." Int J Cancer. October 15, 2026. PMID 42878631. https://doi.org/10.1002/ijc.70753

36. Bhatla N, et al. "Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings." Int J Cancer. October 2026. PMID 42252568. https://doi.org/10.1002/ijc.70534

37. Murtas M, et al. "Resource-Adapted Triage Strategies for Women Testing HPV Positive With Self-Collected Vaginal Samples in Cameroon." Int J Cancer. October 2026. PMID 42312659. https://doi.org/10.1002/ijc.70573

Additional open-access citations:

38. Tao H, et al. "A Holistic Framework for Cervical Cancer Screening and Risk Stratification: Integrating Etiology, Morphology, Epigenetics, and Microecology." Cancer Manag Res. October 8, 2026. PMID 42866570. https://doi.org/10.2147/CMAR.S633709 (integrated framework for screening and risk stratification)

39. Omballa V, et al. "Analytical performance and clinical usability of a low-cost vaginal swab for sensitive detection of high-risk human papillomavirus." Gates Open Res. October 15, 2026. PMID 42892759. https://doi.org/10.12688/gatesopenres.16399.1 (low-cost vaginal swab for HPV detection)

40. Bostanci EI, et al. "Beyond HPV16/18: genotype distribution of high-risk HPV and cycle threshold values in cervical carcinogenesis spectrum." Ann Med. October 15, 2026. PMID 42878366. https://doi.org/10.1080/07853890.2026.2746866 (high-risk HPV genotypes beyond 16/18)

41. Li H, et al. "Cervical cancer screening willingness and associated health beliefs among predominantly college-educated young women attending gynecology clinics in Shenzhen, China." Front Public Health. October 12, 2026. PMID 42935994. https://doi.org/10.3389/fpubh.2026.1969898 (screening willingness among young women, Shenzhen)

42. Zhou L, et al. "FMCerNet: frequency-aware multi-label learning for fine-grained cervical cytology screening." Bioinformatics. October 2, 2026. PMID 42895261. https://doi.org/10.1093/bioinformatics/btag759 (AI model for cervical cytology screening)

43. Leng J, et al. "Knowledge Graphs for Cervical Cancer Across the Care Continuum: From Vaccination and Screening to Personalized Therapy." Ther Clin Risk Manag. October 15, 2026. PMID 42899193. https://doi.org/10.2147/TCRM.S619879 (knowledge graphs across the care continuum)

44. Szmigiel-Soja A, et al. "Psychological distress among women with abnormal cervical cancer screening results in Poland: Validation of the Polish version of the Cervical Dysplasia Distress Questionnaire (CDDQ-PL)." PLoS One. October 13, 2026. PMID 42868113. https://doi.org/10.1371/journal.pone.0360240 (distress scale validation, Polish women with abnormal results)

Related citations, access restricted:

45. Tantengco OAG, et al. "Acceptability and preference of self-collected vaginal samples for human papillomavirus DNA testing compared with physician-collected Pap smear." Sex Health. October 20, 2026. PMID 42764488. https://doi.org/10.1071/SH26069 (subscription access)

46. Mou J, et al. "Advances in isothermal nucleic acid amplification-based HPV assays for cervical cancer screening in low- and middle-income countries: A scoping review." Cancer Epidemiol. October 6, 2026. PMID 42837910. https://doi.org/10.1016/j.canep.2026.103244 (subscription access)

47. Sultana F, et al. "Clinical Evaluation of miR-135b-5p and miR-21-5p Expression on Self-Collected Cervical Swab Samples for Triaging HR-HPV-Positive High-Grade Preneoplastic Lesions in India." Genet Test Mol Biomarkers. October 2026. PMID 42784467. https://doi.org/10.1177/19450265261491098 (subscription access)

48. Zhong X, et al. "Clinical Utility of Cytological Methylation Assay in Cervical Cancer Screening Across Various Cervical Transformation Zones." Int J Cancer. October 2026. PMID 42277588. https://doi.org/10.1002/ijc.70591 (free to read, no reuse license)

49. Lahrmann B, et al. "Closing the Automation Gap in HPV-Based Cervical Cancer Screening: Independent External Validation of an AI Model for Dual-Stain Triage." NEJM AI. October 2026. PMID 42932696. https://doi.org/10.1056/AIoa2600270 (subscription access)

50. Lewis G, et al. "Cost-effectiveness of self-sampling strategies for cervical cancer screening: a commentary." Br J Community Nurs. October 5, 2026. PMID 42832409. https://doi.org/10.12968/bjcn.2025.0211 (subscription access)

51. Xia L, et al. "High-risk Human Papillomavirus Genotypes in Women Undergoing Cervical Screening in Leshan, China: Real-time and Nested Multiplex PCR." J Vis Exp. October 13, 2026. PMID 42872767. https://doi.org/10.3791/72076 (subscription access)

52. Smith CC, et al. "How Would You Screen This 26-Year-Old Woman for Cervical Cancer? Grand Rounds Discussion From Beth Israel Deaconess Medical Center." Ann Intern Med. October 13, 2026. PMID 42863118. https://doi.org/10.7326/ANNALS-26-02904 (subscription access)

53. Alam MS, et al. "HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial." Int J Cancer. October 2026. PMID 42363777. https://doi.org/10.1002/ijc.70616 (restricted license, CC BY-NC-ND 4.0)

54. Corbin H, et al. "Interobserver variability in the interpretation of Papanicolaou tests using the Hologic Genius Digital Diagnostics System: detailed analysis of cytology verification in a large academic laboratory." Am J Clin Pathol. October 10, 2026. PMID 42912745. https://doi.org/10.1093/ajcp/aqag113 (subscription access)

55. Liao X, et al. "Quality Disparities and Recommendation Consistency of Cervical Cancer Screening Guidelines: A Systematic Appraisal With the AGREE II Instrument." J Eval Clin Pract. October 2026. PMID 42929743. https://doi.org/10.1111/jep.70703 (subscription access)

56. Jin D, et al. "Retrospective Analysis of HPV Infection Status and Genotyping in East China: 2023 - 2024." Clin Lab. October 1, 2026. PMID 42847939. https://doi.org/10.7754/Clin.Lab.2025.250942 (subscription access)

57. Hansen J, et al. "Women's experiences, responses, and coping strategies when testing positive for human papillomavirus in cervical cancer screening: A qualitative study." Acta Obstet Gynecol Scand. October 2026. PMID 42504858. https://doi.org/10.1111/aogs.70311 (restricted license, CC BY-NC-ND 4.0)

Researchers are refining how precancerous changes are tracked and treated

Directly referenced:

58. Wang P, et al. "Differential diagnostic value of PAX1 and JAM3 methylation for cervical intraepithelial neoplasia between premenopausal and postmenopausal women: a retrospective clinical study in China." Ann Med. October 4, 2026. PMID 42830604. https://doi.org/10.1080/07853890.2026.2722566

59. Huang Y, et al. "Evaluation of HPV E6/E7 mRNA in predicting recurrence after Leep in cervical intraepithelial neoplasia: A study of negative findings." PLoS One. October 16, 2026. PMID 42886657. https://doi.org/10.1371/journal.pone.0360914

60. Major AL, et al. "Cytokine Profiles in Cervical Intraepithelial Neoplasia: Associations with Lesion Severity and Exploratory Treatment Response." Diagnostics (Basel). October 9, 2026. PMID 42938102. https://doi.org/10.3390/diagnostics16203261

Additional open-access citations:

61. Martínez-Campos C, et al. "Altered immune responses in HR-HPV infected women." Front Med (Lausanne). October 15, 2026. PMID 42959994. https://doi.org/10.3389/fmed.2026.1986999 (immune responses in high-risk HPV infection)

62. Zhou Y, et al. "From HPV infection to cervical precancer: Molecular mechanisms, immune microenvironment and emerging technologies." Cell Mol Life Sci. October 16, 2026. PMID 42888274. https://doi.org/10.1007/s00018-026-06473-x (review of HPV infection to precancer)

63. Yıldız P, et al. "Retrospective study of inflammatory markers in high-grade cervical lesions." Rev Assoc Med Bras (1992). October 5, 2026. PMID 42848650. https://doi.org/10.1590/1806-9282.20260706 (inflammatory markers in high-grade lesions)

64. Molina MA, et al. "Towards a sequential microbiome therapy for HPV-associated cervicovaginal dysbiosis." Commun Biol. October 29, 2026. PMID 42957839. https://doi.org/10.1038/s42003-026-11208-6 (microbiome therapy for cervicovaginal dysbiosis)

65. Liu Y, et al. "Vaginal microbiota and functional prediction along the progression of cervical lesions in postmenopausal women." Front Cell Infect Microbiol. October 2, 2026. PMID 42890774. https://doi.org/10.3389/fcimb.2026.1911664 (vaginal microbiota across lesion progression, postmenopausal women)

Related citations, access restricted:

66. Pareja R, et al. "FIGO/IGCS statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions." Int J Gynaecol Obstet. October 2026. PMID 42677467. https://doi.org/10.1002/ijgo.71285 (subscription access)

67. Cheung LC, et al. "Markers of cervical intraepithelial neoplasia grade 2 regression and subsequent risk of CIN3." J Natl Cancer Inst. October 1, 2026. PMID 42826514. https://doi.org/10.1093/jnci/djag345 (subscription access)

68. Cajas-Salazar N, et al. "Micronucleus cytome assay reveals genomic instability in premalignant cervical lesions among high-risk HPV-positive women." Biotech Histochem. October 9, 2026. PMID 42852509. https://doi.org/10.1080/10520295.2026.2732168 (restricted license, CC BY-NC-ND 4.0)

69. Kong D, et al. "The efficacy comparison of laser ablation combined with photodynamic therapy versus LEEP for women with CIN2/3 of childbearing age: a non-randomized case-control study." Photodiagnosis Photodyn Ther. October 2026. PMID 42457004. https://doi.org/10.1016/j.pdpdt.2026.105577 (restricted license, CC BY-NC-ND 4.0)

70. Mikluš M, et al. "The Role of Methylation Marker FAM19A4/mir124-2 and HPV Genotype in Active Surveillance of Women With Cervical Intraepithelial Neoplasia Grade 2 (CIN2)." J Med Virol. October 2026. PMID 42867141. https://doi.org/10.1002/jmv.71175 (subscription access)

Health disparities and global equity remain the central challenge for prevention

Directly referenced:

71. Esteire I, et al. "Cervical cancer screening in Sub-Saharan Africa: A scoping review of test and treat and test, triage and treat approaches." Public Health. October 2026. PMID 42732708. https://doi.org/10.1016/j.puhe.2026.106445

72. Sefuthi T, et al. "A patient costing analysis of Lesotho's cervical cancer screening program." Front Public Health. October 14, 2026. PMID 42952594. https://doi.org/10.3389/fpubh.2026.1888325

73. Shaban MM, et al. ""Barriers beneath the surface": healthcare access and cultural beliefs affecting cervical cancer screening among egyptian women: a qualitative study." BMC Womens Health. October 17, 2026. PMID 42892682. https://doi.org/10.1186/s12905-026-04911-3

74. Winkler L, et al. "The Role of Self-Collection in Optimising Cervical Screening for People With Intellectual Disability: A Multi Perspective Qualitative Study." Health Expect. October 2026. PMID 42927653. https://doi.org/10.1111/hex.70920

Additional open-access citations:

75. Jarrar R, et al. "Acceptability of a Peer-Led Faith-Based Intervention to Improve Breast, Bowel and Cervical Cancer Screening Uptake Among UK Muslim Women: A Qualitative Evaluation." Health Expect. October 2026. PMID 42886209. https://doi.org/10.1111/hex.70935 (faith-based peer intervention, UK Muslim women)

76. Blythe R, et al. "Age-specific income losses due to HPV-attributable cancers in Singapore." PLoS One. October 30, 2026. PMID 42961926. https://doi.org/10.1371/journal.pone.0361921 (income losses from HPV-attributable cancers, Singapore)

77. Lakshmanasamy R, et al. "Cervical Cancer Elimination in India: Progress, Gaps, and the Priorities." Int J Womens Health. October 13, 2026. PMID 42893273. https://doi.org/10.2147/IJWH.S635866 (progress toward elimination in India)

78. Wu B, et al. "Epidemiological characteristics of cervical cancer in Asian populations and risk factor inference based on Mendelian randomization." Medicine (Baltimore). October 2, 2026. PMID 42826328. https://doi.org/10.1097/MD.0000000000051015 (epidemiology in Asian populations, Mendelian randomization)

79. Carmack C, et al. "Feasibility and proof-of-concept of a cervical cancer prevention edutainment webisode for African American women in Houston, Texas." Int J Public Health. October 14, 2026. PMID 42953550. https://doi.org/10.3389/ijph.2026.1609804 (prevention edutainment webisode, African American women)

80. Tan C, et al. "Impact of the COVID-19 pandemic on diagnosis, treatment, and prognosis of cervical, endometrial, and ovarian cancers: A retrospective cohort study based on the SEER database." Medicine (Baltimore). October 16, 2026. PMID 42888541. https://doi.org/10.1097/MD.0000000000051038 (COVID-19 pandemic and gynecologic cancer care, SEER)

81. Alemu GG, et al. "Precancerous cervical lesions and associated factors among HIV-positive women in Southern and Eastern African countries: A systematic review and meta-analysis." PLoS One. October 23, 2026. PMID 42912824. https://doi.org/10.1371/journal.pone.0361185 (precancer among women with HIV, Southern and Eastern Africa)

82. Inturrisi F, et al. "Scaling HPV Self-Sampling in Low-Resource Settings: From Evidence to Sustainable Implementation." Int J Womens Health. October 12, 2026. PMID 42898094. https://doi.org/10.2147/IJWH.S633156 (scaling HPV self-sampling in low-resource settings)

83. Veeravagu T, et al. "Stakeholders' perspectives on communication gaps in cervical cancer prevention among women of Turkish, Moroccan and Syrian origin: a focus group study in the Netherlands." BMJ Open. October 20, 2026. PMID 42901579. https://doi.org/10.1136/bmjopen-2026-120419 (communication gaps in prevention, migrant women in the Netherlands)

84. Harerimana A, et al. "Text, talk, screen: mapping mHealth interventions for cervical cancer prevention and control in Africa - a scoping review." Front Digit Health. October 15, 2026. PMID 42959596. https://doi.org/10.3389/fdgth.2026.1947988 (mHealth interventions for prevention in Africa)

85. Hendrickx M, et al. "Untimely follow-up after cervical cancer screening: A qualitative study among healthcare providers in Flanders (Belgium)." PLoS One. October 7, 2026. PMID 42842549. https://doi.org/10.1371/journal.pone.0359860 (provider perspectives on delayed follow-up, Belgium)

Related citations, access restricted:

86. Aleshire M, et al. "Acceptability of At-Home hrHPV Cervical Cancer Screening For Transmasculine Individuals: A Qualitative Descriptive Study." West J Nurs Res. October 2026. PMID 42571636. https://doi.org/10.1177/01939459261464522 (subscription access)

87. Xie Y, et al. "Cervical Cancer Screening Rates by Race and Ethnicity, Age, Language, and Census Region." JAMA Netw Open. October 1, 2026. PMID 42886481. https://doi.org/10.1001/jamanetworkopen.2026.39938 (restricted license, CC BY-NC-ND 4.0)

88. Joseph S, et al. "Development and Evaluation of a Trauma-Informed Women's Health Education Program for Intimate Partner Violence Survivors: A Mixed-Methods Study." Violence Vict. October 3, 2026. PMID 42829211. https://doi.org/10.1891/VV-2025-0100 (subscription access)

89. Morenz AM, et al. "Development of an HPV Self-Collection Brochure for Unhoused Individuals Using Learner Verification and Revision." Health Educ Behav. October 25, 2026. PMID 42928652. https://doi.org/10.1177/10901981261497990 (subscription access)

90. Zhu L, et al. "Epidemiological Trends and Global Burden of Cervical Cancer: Insights From the 2021 Global Burden of Disease Study." Physiother Res Int. October 2026. PMID 42894979. https://doi.org/10.1002/pri.70362 (subscription access)

91. McNair A, et al. "Exploring the Social and Financial Impacts of Cervical Cancer on Caregivers in Low- and Middle-Income Countries: A Scoping Review." Psychooncology. October 2026. PMID 42920353. https://doi.org/10.1002/pon.70641 (restricted license, CC BY-NC-ND 4.0)

92. Abbas S, et al. "Health system responsiveness in cervical screening: experiences of Muslim immigrant women in Australia." Aust J Prim Health. October 20, 2026. PMID 42893783. https://doi.org/10.1071/PY26151 (restricted license, CC BY-NC-ND 4.0)

93. Ohaka N, et al. "Institutional and Demographic Barriers to Cervical Cancer Screening among Women in Rivers State, Nigeria." Asian Pac J Cancer Prev. October 1, 2026. PMID 42935074. https://doi.org/10.31557/APJCP.2026.27.10.3809 (license unconfirmed)

94. West J, et al. "Mobile cervical screening: using an opportunistic screening service to increase uptake in underserved communities." Nurs Stand. October 26, 2026. PMID 42929158. https://doi.org/10.7748/ns.2026.e12781 (subscription access)

95. Haury J, et al. "Multiple Dimensions of Social Vulnerability and Cervical Cancer Screening Uptake." JAMA Netw Open. October 1, 2026. PMID 42900473. https://doi.org/10.1001/jamanetworkopen.2026.39570 (restricted license, CC BY-NC-ND 4.0)

96. Hamilton M, et al. "Timeliness of Primary Radiotherapy for Cervical Cancer in Queensland: A 10 Year Rural-Urban Retrospective Cohort Study." Aust N Z J Obstet Gynaecol. October 2026. PMID 42872563. https://doi.org/10.1111/ajo.70185 (restricted license, CC BY-NC-ND 4.0)

Fertility, hormones, and well-being after treatment are getting closer attention

Directly referenced:

97. Margueritte F, et al. "FERTILITY-SPARING SURGERY AND OVARIAN TRANSPOSITION IN CERVICAL CANCER - A REVIEW FROM THE FRENCH CERVICAL CANCER GUIDELINES GROUP." J Gynecol Obstet Hum Reprod. October 27, 2026. PMID 42946052. https://doi.org/10.1016/j.jogoh.2026.103313

98. Gray K, et al. "Hormone replacement after radiotherapy for premenopausal patients with cervical cancer: a retrospective cohort study." J Obstet Gynaecol Can. October 30, 2026. PMID 42962757. https://doi.org/10.1016/j.jogc.2026.103559

99. Scripcariu IS, et al. "Anxiety and Depression in Cervical Cancer Patients in Relation to Nutritional Status and Oxidative Stress." Med Sci (Basel). October 9, 2026. PMID 42930576. https://doi.org/10.3390/medsci14060657

100. Tilahun SW, et al. "Validation of the Amharic Version of the Full and Short Form of the Trust in Oncologist Scale Among Cervical Cancer Patient." Cancer Rep (Hoboken). October 2026. PMID 42864747. https://doi.org/10.1002/cnr2.70718

Related citations, access restricted:

101. Koohachaiskun N, et al. "Effects of Estriol-Lactobacilli Combination Versus Polycarbophil-Based Vaginal Moisturizer on Post-Radiation Vaginitis in Women With Cervical Cancer: A Randomized Controlled Trial." J Obstet Gynaecol Res. October 2026. PMID 42836699. https://doi.org/10.1111/jog.70525 (subscription access)

102. Li C, et al. "Prevalence and independent influencing factors of moderate-to-severe cancer-related fatigue (CRF) and its association with Buzhong-Yiqi (BZYQ) use among patients with locally advanced cervical squamous cell carcinoma (LACSCC): a retrospective observational study using propensity-score weighting (PSW) logistic regression model." Support Care Cancer. October 10, 2026. PMID 42859257. https://doi.org/10.1007/s00520-026-11335-0 (subscription access)

103. Moretti-Marques R, et al. "Radical trachelectomy in Brazil: a multi-institutional review on fertility preservation and oncologic outcomes." Int J Gynecol Cancer. October 2026. PMID 42833759. https://doi.org/10.1016/j.ijgc.2026.104978 (subscription access)

Molecular profiling is starting to sort cervical cancers into treatable groups

Directly referenced:

104. Pan T, et al. "Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients." PLoS Biol. October 5, 2026. PMID 42832529. https://doi.org/10.1371/journal.pbio.3004029

105. Chen J, et al. "MRI-Based Radiomics Model for Pretreatment Prediction of Pathological Lymph Node Metastasis in Neuroendocrine Carcinoma of the Cervix: Dual-Center Development and External Validation." Curr Oncol. October 16, 2026. PMID 42930192. https://doi.org/10.3390/curroncol33100625

106. Dian AL, et al. "Prognostic Impact of ERAP1 Genetic Variants and Haplotypes in Cervical Cancer: Insights From TCGA-CESC and a Brazilian Patient Cohort." Mol Genet Genomic Med. October 2026. PMID 42899476. https://doi.org/10.1002/mgg3.70170

Additional open-access citations:

107. Dwornik R, et al. "Immune Response Gene Polymorphisms and Cervical Cancer Susceptibility." Int J Mol Sci. October 21, 2026. PMID 42942150. https://doi.org/10.3390/ijms27209384 (immune gene polymorphisms and susceptibility)

108. Li X, et al. "Prediction of prognosis and treatment effect of cervical cancer by immunogenic cell death-related genes." PeerJ. October 7, 2026. PMID 42859803. https://doi.org/10.7717/peerj.21635 (immunogenic cell death gene signature)

Related citations, access restricted:

109. Chen J, et al. "Integrating scRNA-Seq and Spatial Transcriptomics Reveal Novel Risk Stratification Signatures in Cervical Carcinoma." J Med Virol. October 2026. PMID 42891568. https://doi.org/10.1002/jmv.71184 (subscription access)

110. Dong B, et al. "Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma." Signal Transduct Target Ther. October 5, 2026. PMID 42830288. https://doi.org/10.1038/s41392-026-02822-1 (restricted license, CC BY-NC-ND 4.0)

111. Zheng LF, et al. "Prognostic Value of MiR-934 and MiR-1260a in Plasma and Early Detection of Metastasis in Patients with Cervical Cancer." Clin Lab. October 1, 2026. PMID 42847945. https://doi.org/10.7754/Clin.Lab.2025.250353 (subscription access)

General and basic-science research continues to map how cervical tumors grow and resist treatment

Additional open-access citations:

112. Reséndiz-Castillo LJ, et al. "Cancer-associated fibroblasts from cervical cancer modulate protumoral neutrophil functions: evidence from a pilot exploratory study." Front Immunol. October 9, 2026. PMID 42920549. https://doi.org/10.3389/fimmu.2026.1900567 (cancer-associated fibroblasts and neutrophils)

113. Merecz-Sadowska A, et al. "Celastrol and Its Derivatives in Breast, Ovarian, and Cervical Cancer: Molecular Targets, Signalling Networks, and Nanocarrier-Based Delivery." Molecules. October 12, 2026. PMID 42943713. https://doi.org/10.3390/molecules31203641 (celastrol in breast, ovarian, and cervical cancer)

114. Liu N, et al. "Dysregulation of the miR-557/MELK axis and its correlation with tumor markers in cervical cancer." Lab Med. October 5, 2026. PMID 42933999. https://doi.org/10.1093/labmed/lmag085 (miR-557/MELK axis and tumor markers)

115. Pan X, et al. "Molecular Targets and Potential Mechanisms of Luteolin Against Cervical Carcinoma: Integrative Approach Combining Network Pharmacology, Molecular Docking, Molecular Dynamics Simulations, and In Vitro Validation." Chem Biodivers. October 2026. PMID 42904790. https://doi.org/10.1002/cbdv.71860 (luteolin, network pharmacology)

116. Fobian SF, et al. "Necroptosis as a key player in cervical cancer progression and management: a systematic review and transcriptomic cross-study consensus analysis." Apoptosis. October 11, 2026. PMID 42859938. https://doi.org/10.1007/s10495-026-02440-w (necroptosis, systematic review)

117. Kornienko TE, et al. "Safety and Antitumor Activity of the Usnic Acid Derivative OL9-116, a TDP1 Inhibitor, as an Adjunctive Therapy in Combination with Topotecan." Int J Mol Sci. October 19, 2026. PMID 42942035. https://doi.org/10.3390/ijms27209266 (TDP1 inhibitor with topotecan, preclinical)

118. Huang L, et al. "Ultrasound-Responsive Nanoplatforms in HPV-Associated Cervical Cancer: Reprogramming the Post-Infection Microenvironment." Int J Nanomedicine. October 22, 2026. PMID 42936177. https://doi.org/10.2147/IJN.S642841 (ultrasound-responsive nanoplatforms)

Related citations, access restricted:

119. Li Y, et al. "A pilot evaluation of ChatGPT-4o-assisted hypothesis generation for exploring potential links between fungal biology and cervical cancer." Antonie Van Leeuwenhoek. October 4, 2026. PMID 42829383. https://doi.org/10.1007/s10482-026-02434-3 (restricted license, CC BY-NC-ND 4.0)

120. Muralidharan P, et al. "ABCB1-Mediated Olaparib Resistance in Cervical Cancer: Molecular Mechanisms and Therapeutic Strategies." J Vis Exp. October 16, 2026. PMID 42891595. https://doi.org/10.3791/72712 (subscription access)

121. Wang J, et al. "Alkaline Phosphatase-Responsive Composite Hydrogels Modulating Tumor Mechanical Properties for Cervical Cancer Therapy." ACS Appl Mater Interfaces. October 14, 2026. PMID 42814851. https://doi.org/10.1021/acsami.6c14164 (subscription access)

122. Ni D, et al. "Discovery of Diaryl Pyrimidine-Guanidine Derivatives as Jumonji C Domain-Containing Lysine Histone Demethylase (KDM) Inhibitors with In Vivo Anti-Cervical Cancer Activity." J Med Chem. October 22, 2026. PMID 42911740. https://doi.org/10.1021/acs.jmedchem.6c01994 (subscription access)

123. Yan T, et al. "Discovery of novel Quinazoline-chalcone hybrids as dual VEGFR-2/P-gp inhibitors to reverse cisplatin resistance in cervical Cancer." Bioorg Chem. October 2026. PMID 42623911. https://doi.org/10.1016/j.bioorg.2026.110411 (subscription access)

124. Pan C, et al. "FAM43B mediates BMAL1-driven regulation of ERK signaling to promote cervical cancer progression." J Mol Histol. October 15, 2026. PMID 42878952. https://doi.org/10.1007/s10735-026-11008-6 (subscription access)

125. Lei H, et al. "Folic Acid-Functionalized Liposomes Co-Loaded with Doxorubicin and Indocyanine Green for Combined Chemophotothermal Therapy of Cervical Cancer." ACS Appl Mater Interfaces. October 28, 2026. PMID 42868217. https://doi.org/10.1021/acsami.6c11448 (subscription access)

126. Kumagai K, et al. "Host chromatin architecture in HPV-driven cervical cancer: molecular mechanisms and therapeutic resistance." Med Oncol. October 8, 2026. PMID 42848106. https://doi.org/10.1007/s12032-026-03445-w (subscription access)

127. Goodarzi M, et al. "HPV-associated extracellular vesicles and the tumor microenvironment: mechanisms of immune modulation and translational implications." Mol Biol Rep. October 30, 2026. PMID 42961687. https://doi.org/10.1007/s11033-026-13091-0 (subscription access)

128. Guo H, et al. "Loperamide enhances the radiosensitivity of cervical cancer cells via ferroptosis induction." Oncol Rep. October 2, 2026. PMID 42825373. https://doi.org/10.3892/or.2026.9203 (restricted license, CC BY-NC-ND 4.0)

129. Colín-Val Z, et al. "Lycopene inhibits proliferation, induces apoptosis, and suppresses migration in cervical cancer cells: involvement of PI3K/Akt signaling." J Mol Histol. October 16, 2026. PMID 42886259. https://doi.org/10.1007/s10735-026-10964-3 (subscription access)

130. Roozbehani M, et al. "Modulation of the NAMPT/SIRT axis in HeLa cells exposed to adipose-derived mesenchymal stem cell-conditioned medium." Mol Biol Rep. October 22, 2026. PMID 42911462. https://doi.org/10.1007/s11033-026-12873-w (subscription access)

131. Mukherjee S, et al. "Modulation of β-Catenin/EMT Axis by Croton caudatus and Its Phytoflavonoid Kaempferol Ameliorates Cervical Cancer Migration and Stemness." FASEB J. October 31, 2026. PMID 42888968. https://doi.org/10.1096/fj.202504700R (subscription access)

132. Mo X, et al. "Multifaceted HPV16 E2 as a potential therapeutic target for cervical cancer and beyond." Mol Biol Rep. October 30, 2026. PMID 42961685. https://doi.org/10.1007/s11033-026-12813-8 (subscription access)

133. Lu L, et al. "RSPO1-LGR4 axis drives cervical cancer progression via activation of the EGFR/Src/ERK/AKT signaling pathway." Neoplasia. October 7, 2026. PMID 42843207. https://doi.org/10.1016/j.neo.2026.101374 (restricted license, CC BY-NC-ND 4.0)

134. Yang H, et al. "Salvianolic Acid B Suppresses Epithelial-Mesenchymal Transition-Associated Phenotypes in Cervical Cancer Cells via GPIb Alpha/LYN/TWIST1 Signaling." J Vis Exp. October 13, 2026. PMID 42872708. https://doi.org/10.3791/72216 (subscription access)

135. Tawfeek HM, et al. "Spotlights on cervical cancer: progression, diagnosis and clinical manifestations, epidemiology, treatment approaches, role of artificial intelligence and future directions." Drug Dev Ind Pharm. October 15, 2026. PMID 42803760. https://doi.org/10.1080/03639045.2026.2741083 (subscription access)

136. Li R, et al. "Targeting P2YR inhibits proliferation of cervical cancer cells and organoids and activates cAMP/PKA/CREB signaling pathway." Purinergic Signal. October 14, 2026. PMID 42873384. https://doi.org/10.1007/s11302-026-10192-0 (restricted license, CC BY-NC-ND 4.0)

137. Srisuphan R, et al. "The neolignan Miliusin B inhibits cell migration and promotes apoptotic cell death in cervical cancer cell line HeLa." Med Oncol. October 20, 2026. PMID 42900416. https://doi.org/10.1007/s12032-026-03457-6 (subscription access)

138. Zhang Y, et al. "Ubiquitin-specific proteases and the immune microenvironment in cervical cancer: mechanistic evidence, immunotherapy resistance, and therapeutic perspectives." Neoplasia. October 20, 2026. PMID 42900981. https://doi.org/10.1016/j.neo.2026.101378 (restricted license, CC BY-NC-ND 4.0)

A note on how this digest was made: This edition was built by searching PubMed for papers published in October 2026, using a two-tier strategy: targeted thematic searches across the cervical cancer landscape (treatment, immunotherapy, ADCs, HPV vaccination, screening, disparities, surgery, molecular subtypes, precancer, survivorship, and rare subtypes) plus a dedicated qualitative search and a broad MeSH sweep. Papers summarized in full are open access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.